Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

David Michael Williams, Executive Vice President and Chief Information & Digital Officer at Merck (NSE:PROR) & Co., Inc.

Merck’s problems in China seem to be getting worse, raising questions about the company’s growth. Trouble with sales of Merck ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...

Analyst at TD Cowen said Merck (NSE:PROR)'s valuation would likely bottom out in 2026, two years before Keytruda's U.S. patent expires in 2028. "The story other than Keytruda has not improved ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other important news updates investors shouldn’t miss. Investor optimism is still strong despite ...

Merck's new products have mitigated the generic competition, offsetting the recent major patent losses. In particular, Keytruda for cancer represents a key blockbuster with multi-billion-dollar ...

TD Cowen downgraded Merck (MRK) to Hold from Buy with a price target of $100, down from $121. The firm says its Buy thesis “broke down” with ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil ...